who's who

3 Houston innovators to know this week

This week's Houston innovators to know includes Rebecca Vaught of Van Heron Labs, Samantha Lewis of GOOSE Capital, and Camilo Mejia of Enovate Upstream. Courtesy photos

Editor's note: Houston entrepreneurs are like the city itself — resilient. And much like the wildcatters that preceded them, they are self-starters and hard working. This week's roundup of Houston innovators all reflect these attributes — whether they're founding their company amid a global pandemic or rebranding a 15-year-old investing institution.

Rebecca Vaught, co-founder of Van Heron Labs

Entrepreneur hopes to bring microbiology into the future with her Houston-based, pandemic-founded startup

Rebecca Vaught started her biotech company just ahead of COVID-19, but she shares on the Houston Innovators Podcast that it's meant more opportunities than challenges. Photo courtesy of Van Heron Labs

When Rebecca Vaught's accelerator program shutdown due to COVID-19, she didn't let that stop the progress for here fledgling biotech business. In fact, it was a turning point.

"A lot of people probably would have seen that as the stopping point but that was actually the beginning of the company," Vaught says on the Houston Innovators Podcast. "What it allowed us to do was actually establish the lab and do the hard work."

As Vaught says, the biotech company, Van Heron Labs, is what it is thanks to the pandemic — not just in spite of it. Click here to read more and listen to the podcast episode.

Samantha Lewis, director of GOOSE Capital

Samantha Lewis, director of GOOSE Capital, shares how the investment firm has rebranded and is focused on the future. Photo courtesy of GOOSE

A prominent investment group, GOOSE Capital — previously known as GOOSE Society of Texas — has opted for a rebranding to move itself into the future for Seed and Series A investment. Samantha Lewis, director of GOOSE, explains the decision means more than just a new name and upgraded website.

"As for the future of GOOSE Capital, expect great things," she tells InnovationMap. "Our rebranding is one of the many steps we are taking to solidify our position in the Seed and Series A venture scene."

Rather than operating as a fund, the GOOSE Capital model enables its corps of investors comprised of Fortune 500 execs and successful serial entrepreneurs direct access to a portfolio of startups and investment deals. At the same time, GOOSE's portfolio companies are able to receive support from these investors. Click here to read more.

Camilo Mejia, CEO and founder of Enovate Upstream

Houston entrepreneur plans to revolutionize and digitize the energy industry

Camilo Mejia, CEO and founder of Houston-based Enovate Upstream, has big plans for increasing efficiency across the oil and gas sector. Photo courtesy of Enovate

Enovate Upstream announced its new artificial intelligence platform that aims to digitize the oil and gas sector to provide the best efficiency and return on investment at every stage of the supply chain cycle — from drilling and production to completion.

"We see a better future in the oil and gas industry," Mejia shares in an interview with InnovationMap. "Our team worked in various roles in O&G, and we don't think the industry will end up as some people may think. The future will be different and digitized, we are just here to facilitate that transition to give back to the industry that gave us a lot."

The company's proprietary cloud-based ADA AI digital ecosystem is challenging the assumptions of the industry by using new technology powered artificial intelligence to provide historical data with AI to give real-time production forecasting. Thanks to the cloud, users can access the information anywhere in the world. Click here to read more.

Trending News

Building Houston

 
 

From a low-cost vaccine to an app that can help reduce exposure, here are the latest COVID-focused and Houston-based research projects. Photo via Getty Images

While it might seem like the COVID-19 pandemic has settled down for the time being, there's plenty of innovative research ongoing to create solutions for affordable vaccines and tech-enabled protection against the spread of the virus.

Some of that research is happening right here in Houston. Here are two innovative projects in the works at local institutions.

UH researcher designs app to monitor best times to shop

A UH professor is putting safe shopping at your fingertips. Photo via UH.edu

When is the best time to run an errand in the pandemic era we currently reside? There might be an app for that. Albert Cheng, professor of computer science and electrical and computer engineering at the University of Houston, is working on a real-time COVID-19 infection risk assessment and mitigation system. He presented his plans at the Institute of Electrical and Electronics Engineers conference HPC for Urgent Decision Making and will publish the work in IEEE Xplore.

Cheng's work analyzes up-to-date data from multiple open sources to see when is the best time to avoid crowds and accomplish activities outside the home.

"Preliminary work has been performed to determine the usability of a number of COVID-19 data websites and other websites such as grocery stores and restaurants' popular times and traffic," Cheng says in a UH release. "Other data, such as vaccination rates and cultural factors (for example, the percentage of people willing to wear facial coverings or masks in an area), are also used to determine the best grocery store to shop in within a time frame."

To use the app, a user would input their intended destinations and the farthest distance willing to go, as well as the time frame of the trip. The risk assessment and mitigation system, or RT-CIRAM, then "provides as output the target location and the time interval to reach there that would reduce the chance of infections," said Cheng.

There's a lot to it, says Cheng, and the process is highly reliant on technology.

"We are leveraging urgent high-performance cloud computing, coupled with time-critical scheduling and routing techniques, along with our expertise in real-time embedded systems and cyber-physical systems, machine learning, medical devices, real-time knowledge/rule-based decision systems, formal verification, functional reactive systems, virtualization and intrusion detection," says Cheng.

2 Houston hospitals team up with immunotherapy company for new vaccine for Africa

The new vaccine will hopefully help mitigate spread of the disease in Sub-Saharan Africa. Photo via bcm.edu

Baylor College of Medicine and Texas Children's Hospital have teamed up with ImmunityBio Inc. — a clinical-stage immunotherapy company — under a licensing agreement to develop a safe, effective and affordable COVID-19 vaccine.

BCM has licensed out a recombinant protein COVID-19 vaccine candidate that was developed at the Texas Children's Hospital Center for Vaccine Development to ImmunityBio. According to the release, the company engaged in license negotiations with the BCM Ventures team, about the vaccine that could address the current pandemic needs in South Africa.

"We hope that our COVID-19 vaccine for global health might become an important step towards advancing vaccine development capacity in South Africa, and ultimately for all of Sub-Saharan Africa," says Dr. Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children's Hospital Center for Vaccine Development.

ImmunityBio, which was founded in 2014 by Dr. Patrick Soon-Shiong, is working on innovative immunotherapies that address serious unmet needs in infectious diseases, according to a news release from BCM.

"There is a great need for second-generation vaccines, which are accessible, durable and offer broad protection against the emerging variants," says Soon-Shiong. "ImmunityBio has executed on a heterologous ("mix-and-match") strategy to develop a universal COVID-19 vaccine. To accomplish this, we have embarked upon large-scale good manufacturing practices and development of DNA (adenovirus), RNA (self-amplifying mRNA) and subunit protein (yeast) vaccine platforms. This comprehensive approach will leverage our expertise in these platforms for both infectious disease and cancer therapies."

Trending News